## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($116.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. CapWealth Advisors LLC Has $27.04 Million Stock Holdings in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260102T093753 | Somewhat-Bullish | Relevance: 100%
- CapWealth Advisors LLC reduced its stake in Gilead Sciences by 3.7% in Q3, holding 243,607 shares valued at $27.04 million, yet it remains their 16th largest holding. Despite this trimming, major institutional investors significantly increased their positions, raising overall institutional ownership to 83.67%. Analysts maintain a "Moderate Buy" rating for Gilead, with a consensus price target of $131.68, following a strong Q3 earnings beat and a declared quarterly dividend.

**2. Lee Johnson Capital Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251231T120912 | Bullish | Relevance: 100%
- Lee Johnson Capital Management LLC has acquired a new stake of 22,606 shares in Gilead Sciences, Inc. (NASDAQ:GILD), valued at approximately $2.51 million, as disclosed in its latest 13F filing. This investment comes as Gilead reported strong Q3 results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $131.68, despite recent insider share sales.

**3. Miracle Mile Advisors LLC Buys 25,117 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260102T110105 | Somewhat-Bullish | Relevance: 100%
- Miracle Mile Advisors LLC significantly increased its stake in Gilead Sciences by 279.5% in Q3, purchasing an additional 25,117 shares to hold a total of 34,104 shares valued at approximately $3.79 million. This increased institutional interest comes despite recent insider selling, with analysts maintaining a "Moderate Buy" consensus rating and a target price of $131.68 for Gilead Sciences (NASDAQ:GILD).

**4. Bank Pictet & Cie Europe AG Boosts Holdings in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20260102T084011 | Bullish | Relevance: 100%
- Bank Pictet & Cie Europe AG significantly increased its stake in Gilead Sciences, Inc. by 502.8% in Q3, now holding 15,288 shares valued at $1.697 million. This move comes as Gilead Sciences exceeded Q3 earnings and revenue estimates and maintains a "Moderate Buy" consensus rating from analysts with an average price target of $131.68. Despite significant institutional ownership, insiders have recently sold over 136,000 shares.

**5. Morgan Stanley Expects Gilead Sciences (GILD) to Thrive as Biopharma Policy Uncertainties Fade in 2026**
- Source: Yahoo Finance Singapore | 20251231T170751 | Bullish | Relevance: 100%
- Morgan Stanley raised its price target on Gilead Sciences (GILD) to $151 from $147, maintaining an Overweight rating, as biopharma policy uncertainties are expected to diminish. The firm anticipates a shift in market focus back to the industry's fundamentals. Gilead also announced positive Phase 3 clinical trial results for a new HIV-1 treatment, reinforcing its commitment to HIV innovation and providing a foundation for future regulatory submissions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $151 | $147 | +3% |
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Overweight |
| 2025-12-10 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($10.00M) |
| Sells | 13 ($5.91M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $5.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.23 indicates undervaluation relative to growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.9B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.23 |
| Forward P/E | 13.9 |
| Current P/E | 14.9 |
| YoY Growth | 7.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 0.3% to -1.1% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). RSI neutral at 46. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.12% (CS: 20) | Neutral |
| RSI_14 | 45.7 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 0.994x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 1.069x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $121.60
- **Stop Loss:** $116.66 (4.1% risk)
- **Target:** $126.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 291
- **Position Value:** $35,385.60
- **Portfolio %:** 35.39%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*